NCT07214727View on ClinicalTrials.gov

A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 9, 2025

Primary Completion Date

March 31, 2030

Study Completion Date

March 31, 2030

Conditions
Alzheimer's Disease
Interventions
DRUG

ALN-5288

ALN-5288 will be administered IT.

DRUG

Placebo

Placebo will be administered IT.

Trial Locations (13)

8036

Clinical Trial Site, Barcelona

28040

Clinical Trial Site, Madrid

K1Z 1G3c

Clinical Trial Site, Ottawa

M3B 257

Clinical Trial Site, Toronto

M5T 2S8

Clinical Trial Site, Toronto

5223 LA

Clinical Trial Site, 's-Hertogenbosch

1081 GN

Clinical Trial Site, Amsterdam

08195

Clinical Trial Site, Catalonia

G15 6PX

Clinical Trial Site, Glasgow

WC1N 3BG

Clinical Trial Site, London

M8 5RB

Clinical Trial Site, Manchester

S10 2HQ

Clinical Trial Site, Sheffield

SO16 6YD

Clinical Trial Site, Southampton

Sponsors
All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Alnylam Pharmaceuticals

INDUSTRY